fasciitis complicating subcutaneous injection of interferon beta
Clicks: 125
ID: 213523
2000
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
125 views
14 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #153 of 250 articles by views in indian journal of pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Data pertaining to 65 patients treated at
the Health Sciences Center Hepatology Research Unit in Winnipeg,
Manitoba describing local complications related to subcutaneous
interferon (IFN) injection administered to treat hepatitis C
virus infection are presented. Nine patients experienced local erythematous
reactions at the injection region. No life-threatening
complications were identified. One case of fasciitis complicating
IFN injection – a complication not previously reported – was successfully
managed with surgical debridement and antibiotic therapy.
This case is a dramatic example of why sterile technique
during infections must be adhered to.
| Reference Key |
cooper2000canadianfasciitis
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Curtis L Cooper;Rachel Gerstein;Kelly Kaita |
| Journal | indian journal of pharmacology |
| Year | 2000 |
| DOI |
10.1155/2000/969163
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.